 Hepatitis
C Top News Articlespatitis
|
• | Tenofovir
May Be More Effective and Less Expensive than Lamivudine (Epivir-HBV) and Adefovir
(Hepsera) as First-line Treatment for HBeAg- Chronic Hepatitis B -
5/09/08 |
• | Lamivudine
(Epivir-HBV) plus Adefovir (Hepsera) Is an Effective Regimen for Lamivudine-resistant
HBV Patients Who Develop Resistance to Entecavir (Baraclude) -
5/09/08 |
• | Pegylated
Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
-
5/09/08 |
• | Entecavir
(Baraclude) Produces Greater Decrease in HBV DNA than Adefovir (Hepsera) in Treatment-naive
HBeAg+ Patients: 96 Week Data from EARLY Study -
5/06/08 |
• | Three
Years of Continuous Entecavir (Baraclude) in Chinese Patients with Prior Lamivudine
(Epivir-HBV) Failure: Studies ETV-056 and ETV-050 -
5/06/08 |
• | Entecavir
(Baraclude) Treatment in Japanese Nucleoside-naive Chronic Hepatitis B Patients
-
5/06/08 |
• | R.E.V.E.A.L.-HBV
Study Shows Persistently High Hepatitis B Viral Load Raises the Risk of Liver
Cancer -
4/29/08 |
• | Tenofovir
(Viread) Is Effective in Chronic Hepatitis B Patients with Prior Nucleoside/nucleotide
Experience -
4/29/08 |
• | European
Commission Approves Tenofovir (Viread) for Chronic Hepatitis B -
4/29/08 |
• | European
Association for the Study of the Liver (EASL) Meeting Opens in Milan -
4/24/08 |
• | Pegasys
Demonstrates Continued Benefits for Chronic Hepatitis B Patients at 4 Year
-
4/24/08 |
• | Gilead
Announces 72-Week Data from Pivotal Studies of Tenofovir (Viread) for Chronic
Hepatitis B -
4/24/08 |
• | Lamivudine
(Epivir-HBV) Monotherapy versus Lamivudine plus Adefovir (Hepsera) for Chronic
Hepatitis -
4/11/08 |
• | Study
Looks at Impact of Hepatitis B Disease Progression on Quality of Life -
4/04/08 |
• | FDA
Grants Orphan Drug Approval of Hepatitis B Immune Globulin to Prevent Post-transplant
Recurrence -
4/04/08 |
• | Five-year
Data Show Continued Low Rate of Resistance to Entecavir (Baraclude) in Chronic
Hepatitis B Patients -
3/28/08 |
• | Has
the Time Come for Expanded Off-label Use of Combination Treatment for Chronic
Hepatitis B? -
3/21/08 |
• | Tenofovir
(Viread) plus Lamivudine (Epivir-HBV) Appears Effective as Rescue Therapy for
Cirrhotic Patients with Resistance to Adefovir (Hepsera) -
3/21/08 |
• | European
Medicines Agency Gives Positive Opinion on Tenofovir (Viread) for Treatment of
Chronic Hepatitis B -
3/21/08 |
• | Canadian
Health Officials Warn against Use of Tebivudine (Tyzeka/Sebivo) in Combination
with Interferons -
3/18/08 |
• | Occult
Hepatitis B Virus in Individuals without Liver Disease -
3/14/08 |
• | Vaccination
Dramatically Cuts Hepatitis B in Italy, but Concerns Remain -
3/11/08 |
• | Hepatitis
B: Reflections on the Current Approach to Antiviral Therapy -
3/07/08 |
• | Adefovir
(Hepsera) for Treatment of Patients with Chronic Hepatitis B Resistant to Lamivudine
(Epivir-HBV) -
3/04/08 |
• | Likelihood
of Adefovir (Hepsera) Resistance in Nucleoside-naive Hepatitis B Patients
-
2/29/08 |
• | HBeAg
and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for Chronic Hepatitis
B -
2/19/08 |
• | Tenofovir
(Viread) Is Effective after Adefovir (Hepsera), but Not Vice Versa -
2/01/08 |
• | Lamivudine
Prevents HBV Reactivation in Immunosuppressed Patients -
1/29/08 |
• | Disease
Progression in Patients with HBeAg-negative Chronic Hepatitis B -
1/29/08 |
• | Hepatitis
B Exacerbation May Occur in Women after Giving Birth -
1/25/08 |
• | Overview
of the Natural History of Chronic Hepatitis B -
1/18/08 |
• | Long-term
Response to Lamivudine (Epivir-HBV) in Children with Chronic Hepatitis -
1/18/08 |
• | Relation
between HBV "X" Gene Integration and Development of Hepatocellular Carcinoma
-
1/14/08 |
• | Once-daily
Clevudine Demonstrates Early HBV Suppression and Biochemical Improvement in Hepatitis
B Patients with Liver Cirrhosis -
1/14/08 |
• | Extended
Duration Pegylated Interferon Alfa-2a (Pegasys) for Patients with HBeAg Negative
Chronic Hepatitis B -
1/11/08 |
• | HBV
Viral Load at Week 4 of Lamivudine (Epivir-HBV) Treatment Predicts Response at
5 Years -
1/08/08 |
• | Two
Studies Show Telbivudine (Tyzeka) Is Superior to Lamivudine (Epivir-HBV) for Chronic
Hepatitis B -
1/08/08 |
• | Telbivudine
(Tyzeka) Superior to Adefovir (Hepsera) at 52 Weeks -
1/04/08 |
• | Clinical
Significance of Persistently Normal ALT in Chronic Hepatitis B Patients -
1/04/08 |
• | Individuals
with Hepatitis B Virus Genotype C Experience HBeAg Clearance Later and Less Often
-
12/14/07 |
• | Hepatitis
Reactivation Following HBeAg Seroconversion -
12/14/07 |
• | Entecavir
(Baraclude) for Chronic Hepatitis B Provides Continued Benefits through 96 Week
-
12/11/07 |
• | Resistance
to Adefovir (Hepsera) Is Uncommon after 3 Years in Hepatitis B Patients Treated
with Adefovir plus Lamivudine (Epivir-HBV) -
12/11/07 |
• | Effect
of Lamivudine (Epivir-HBV) and Adefovir (Hepsera) in Preventing Hepatocellular
Carcinoma -
12/07/07 |
• | Impact
of Adefovir (Hepsera) on Liver Fibrosis and Histological Activity Assessed Using
FibroTest-ActiTest in Hepatitis B Patients -
12/07/07 |
• | Liver
Stiffness Measurement (FibroScan) More Useful for Assessing Fibrosis in Patients
with HCV Compared with HBV -
12/04/07 |
• | Chronic
Hepatitis B Patients May Have Significant Liver Disease Despite Normal ALT-
12/04/07 |
• | Preemptive
Lamivudine Therapy Reduces Risk of Liver Disease Flares in Hepatitis B Patients
Starting Cancer Chemotherapy - 11/30/07 |
• | Pegylated
Interferon Alfa-2a (Pegasys) plus Ribavirin for Patients with HBV and HCV Coinfection
-
11/30/07 |
• | New
Data on Telbivudine (Tyzeka) for Treatment of Chronic Hepatitis B -
11/27/07 |
• | Decline
in Number of Patients Requiring Liver Transplants Due to Hepatitis B -
11/27/07 |
• | Digestive
Disease Week (DDW) 2008 Online Abstract Submissions Due December 1 -
11/27/07 |
• | Predictors
and Long-term Outcomes Associated with Hepatitis B Surface Antigen (HBsAg) Clearance
-
11/20/07 |
• | Chronic
Hepatitis B Patients with Low HBV Viral Load Still Have an Elevated Risk of Liver
Cancer: R.E.V.E.A.L.-HBV Study -
11/16/07 |
• | Gender
Difference in the Natural Course of HBeAg-Positive Chronic Hepatitis B -
11/13/07 |
• | Tenofovir
(Viread) Is Superior to Adefovir (Hepsera) at 48 Weeks for Both HBeAg Positive
and HBeAg Negative Patients with Chronic Hepatitis B
- 11/09/07 |
• | Entecavir
(Baraclude) Maintains HBV Suppression through 4 Years in Nucleoside-naive HBeAg
Positive Patients -
11/06/07 |
• | Hepatitis
B Virus DNA Found in 16th Century Mummy in Korea -
11/06/07 |
• | 12
Weeks of Pegylated Interferon Works as Well as 48 Weeks in Selected Patients with
HBeAg Positive Chronic Hepatitis B -
11/03/07 |
• | Interferon
for the Treatment of Chronic Hepatitis Delta -
10/26/07 |
| • | Clinical
Significance of Persistently Normal ALT in Chronic Hepatitis B Patient -
10/23/07 |
| • | Specific
HBV Mutations Predict Loss of Sensitivity to Lamivudine (Epivir-HBV) -
10/23/07 |
| • | Hepatitis
B Patients Who Spontaneously Clear HBeAg and Achieve Sustained Remission have
Reduced Liver Fibrosis Progression - 10/19/07 |
• | Impaired
Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most
HBeAg-Negative Patients -
10/16/07 |
• | Gilead
Sciences Seeks U.S. and European Marketing Approval for Tenofovir (Viread) for
Treatment of Chronic Hepatitis B -
10/16/07 |
• | HBV
Genotype and Baseline Viral Load Predict Response to Adefovir (Hepsera) in Lamivudine-resistant
Chronic Hepatitis B Patients -
10/12/07 |
• | Pharmasset
Starts Two 48-week Phase 3 Registration Studies of Clevudine for Hepatitis B
- 10/05/07
|
• | Maxygen
Announces Hold on Development of MAXY-alpha (R7025) for Treatment of Hepatitis
B and C -
9/28/07 |
• | Good
Hepatitis B Treatment Outcomes in Patients with Advanced Liver Fibrosis or Cirrhosis
- 9/14/07
|
• | Occult
HBV Coinfection Associated with Poorer Response to Hepatitis C Treatment -
9/14/07 |
• | Prevention
of Variceal Bleeding in Candidates Awaiting Liver Transplantation -
9/11/07 |
• | Primary
Biliary Cirrhosis Is More Severe in African-American and Hispanic Patients Compared
to Caucasians -
9/11/07 |
• | HCV
and HBV Spreading More Slowly among Injection Drug Users in San Francisco
- 9/07/07
|
• | Sorafenib
(Nexavar) Demonstrates Promising Results for Hepatocellular Carcinoma -
9/07/07 |
• | Coffee
Consumption May Reduce the Risk of Liver Cancer - 8/31/07 |
• | Differences
in Response to a Hepatitis B Vaccine Booster among Children and Adolescents Vaccinated
during Infancy -
8/28/07 |
• | Experimental
Hepatitis B Vaccine Aims to Prevent HBV Reinfection after Living Donor Liver Transplantation
-
8/28/07 |
• | Presence
of Mixed Hepatitis B Genotypes Occurs More Frequently in HIV-HBV Coinfected Patients
- 8/17/07 |
• | Liver
Disease and Survival Outcomes in HIV-HBV Coinfected Individuals - 8/17/07 |
• | Community-based
Study in Taiwan Provides More Evidence of Link between Hepatitis C and Type 2
Diabetes - 8/17/07 |
• | Studies
Examine Occult HBV Infection in HIV Positive and HIV-HCV Coinfected Patients
- 8/14/07
|
• | Efficacy
and Safety of Boosted Fosamprenavir (Lexiva) versus Lopinavir/ritonavir (Kaletra)
in Treatment-naive HIV Patients with Hepatitis B or C Coinfection in the KLEAN
Study - 8/07/07 |
• | Sodium
Levels Can Help Predict Outcomes before and after Liver Transplantation - 8/07/07 |
